Hans H Adomat
Overview
Explore the profile of Hans H Adomat including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
796
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Yenki P, Bhasin S, Liu L, Nabavi N, Cheng C, Tam K, et al.
Endocr Relat Cancer
. 2023 Oct;
30(12).
PMID: 37800655
Intratumoral androgen biosynthesis contributes to castration-resistant prostate cancer progression in patients treated with androgen deprivation therapy. The molecular mechanisms by which castration-resistant prostate cancer acquires the capacity for androgen biosynthesis...
2.
Yenki P, Adomat H, Ong C
Prostate
. 2021 Jan;
81(6):309-317.
PMID: 33503318
Background: Castration resistant prostate cancer progression is associated with an acquired intratumoral androgen synthesis. Signaling pathways that can upregulate androgen production in prostate tumor microenvironment are not entirely known. In...
3.
Cucchiara V, Yang J, Liu C, Adomat H, Guns E, Gleave M, et al.
Mol Cancer Ther
. 2019 Jul;
18(10):1811-1821.
PMID: 31341032
Hormone therapy is currently the mainstay in the management of locally advanced and metastatic prostate cancer. Degarelix (Firmagon), a gonadotropin-releasing hormone (GnRH) receptor antagonist differs from luteinizing hormone-releasing hormone (LHRH)...
4.
Gordon J, Noble J, Midha A, Derakhshan F, Wang G, Adomat H, et al.
Cancer Res
. 2019 May;
79(13):3320-3331.
PMID: 31064850
Aberrant cholesterol metabolism is increasingly appreciated to be essential for prostate cancer initiation and progression. Transcript expression of the high-density lipoprotein-cholesterol receptor scavenger receptor B1 (SR-B1) is elevated in primary...
5.
Shrestha R, Nabavi N, Lin Y, Mo F, Anderson S, Volik S, et al.
Genome Med
. 2019 Feb;
11(1):8.
PMID: 30777124
Background: Malignant peritoneal mesothelioma (PeM) is a rare and fatal cancer that originates from the peritoneal lining of the abdomen. Standard treatment of PeM is limited to cytoreductive surgery and/or...
6.
Fokidis H, Ma C, Radin B, Prior N, Adomat H, Guns E, et al.
J Comp Neurol
. 2018 Sep;
527(2):347-361.
PMID: 30225913
The transition between the breeding and nonbreeding states is often marked by a shift in energy balance. Despite this well-known shift in energy balance, little work has explored seasonal differences...
7.
Lallous N, Leblanc E, Munuganti R, Hassona M, Al Nakouzi N, Awrey S, et al.
Mol Cancer Ther
. 2016 Oct;
15(12):2936-2945.
PMID: 27765852
The development of new antiandrogens, such as enzalutamide, or androgen synthesis inhibitors like abiraterone has improved patient outcomes in the treatment of advanced prostate cancer. However, due to the development...
8.
Lubik A, Nouri M, Truong S, Ghaffari M, Adomat H, Corey E, et al.
Int J Cancer
. 2016 Sep;
140(2):358-369.
PMID: 27672740
Despite the substantial benefit of androgen deprivation therapy (ADT) for metastatic prostate cancer, patients often progress to castration-resistant disease (CRPC) that is more difficult to treat. CRPC is associated with...
9.
Elisia I, Nakamura H, Lam V, Hofs E, Cederberg R, Cait J, et al.
PLoS One
. 2016 Apr;
11(3):e0152538.
PMID: 27031833
Dimethyl sulfoxide (DMSO) is currently used as an alternative treatment for various inflammatory conditions as well as for cancer. Despite its widespread use, there is a paucity of data regarding...
10.
Prior N, Yap K, Mainwaring M, Adomat H, Crino O, Ma C, et al.
Gen Comp Endocrinol
. 2016 Feb;
244:108-117.
PMID: 26899721
The zebra finch is a common model organism in neuroscience, endocrinology, and ethology. Zebra finches are generally considered opportunistic breeders, but the extent of their opportunism depends on the predictability...